12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xtandi enzalutamide regulatory update

FDA approved once-daily Xtandi enzalutamide well ahead of the oral prostate cancer drug's Nov. 22 PDUFA date. Xtandi is indicated to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with docetaxel. The partners will co-commercialize the product, with a launch planned for mid-September....

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >